AbbVie Inc. (TSX:ABBV)
Canada · Delayed Price · Currency is CAD | Market Cap | 668.92B +11.1% |
| Revenue (ttm) | 91.43B +10.4% |
| Net Income | 8.90B +67.7% |
| EPS | 5.03 +68.5% |
| Shares Out | n/a |
| PE Ratio | 75.13 |
| Forward PE | 17.58 |
| Dividend | 1.20 (3.25%) |
| Ex-Dividend Date | Oct 15, 2026 |
| Volume | 7,298 |
| Open | 36.17 |
| Previous Close | 36.61 |
| Day's Range | 36.16 - 37.06 |
| 52-Week Range | 26.89 - 37.16 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2026 |
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medi... [Read more]
Financial Performance
In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.19 billion, a decrease of -1.23%.
Financial numbers in USD Financial StatementsNews
AbbVie sees Q3 EPS $3.73-$3.77, consensus $3.84
The company states: “Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2026 are expected to include acquired IPR&D and milestones expense of $216 million on a…
AbbVie sees FY26 EPS $13.76-$13.96, consensus $14.01
16:31 EDT AbbVie (ABBV) sees FY26 EPS $13.76-$13.96, consensus $14.01
AbbVie blood cancer drug combo cuts risk of progression or death in late-stage study
Danish biotech firm Genmab and US drugmaker AbbVie said on Monday their combination treatment for patients newly diagnosed with a type of lymphoma reduced the risk of disease progression or death in...
Genmab, AbbVie report epcoritamab combination demonstrates improved PFS in study
Genmab A/S (GMAB) and AbbVie (ABBV) announced “positive” topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody ad...
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS)...
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Company Announcement COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; October 5, 2026 EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically si...
AbbVie joins US government pilot to test drug discount rebates
US drugmaker AbbVie said on Friday it would participate in a US government pilot program aimed at testing a new rebate system for discounted medicines.
AbbVie presents long-term RINVOQ data at EADV Congress
AbbVie (ABBV) announced late-breaking results from the ongoing Phase 3 Viti-Up-1 and Viti-Up-2 studies of RINVOQ in non-segmental vitiligo, showing continued facial and total body repigmentation throu...
AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo
RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) who are candidates for systemic therapy Phase 3...
AbbVie to Host Third-Quarter 2026 Earnings Conference Call
NORTH CHICAGO, Ill., Oct. 1, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2026 financial results on Friday, October 30, 2026, before the market opens.
AbbVie reports Phase 1 data for ABBV-295
AbbVie (ABBV) announced that detailed results from the multiple ascending dose part of its Phase 1 study evaluating ABBV-295 will be presented in a short oral presentation at the European…
AbbVie reports ‘positive’ results from Phase 2 APEX Part B study of zumilokibart
AbbVie (ABBV) announced that the primary results from the ongoing Phase 2 APEX Part B Dose-Regimen-Finding Study, evaluating zumilokibart, in adult patients with moderate to severe atopic dermatitis w...
AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026
Detailed findings, to be presented in a short oral presentation, demonstrated an approximately 11- to 12-day half-life and dose-proportional increases in plasma exposure, supporting evaluation of ABBV...
AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026
Phase 2 data in adults with atopic dermatitis showed that all three zumilokibart dose regimens met the primary endpoint, with significantly greater improvements in Eczema Area and Severity Index -75 (...
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
AbbVie presents 60 abstracts and presentations from a robust portfolio spanning across alopecia areata, atopic dermatitis, hidradenitis suppurativa, non-segmental vitiligo, psoriasis and psoriatic art...
AbbVie partners with Valkai to apply advanced AI across clinical development
AbbVie (ABBV) is investing in its AI infrastructure through a new partnership with Valkai, a life sciences AI platform designed to help accelerate the pace at which scientific innovation reaches…
AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development
AbbVie deepens investment in artificial intelligence (AI) by entering into a new collaboration with Valkai to strengthen integrated AI capabilities across clinical development AbbVie is committed to i...
Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
BOSTON--(BUSINESS WIRE)--Ginkgo Datapoints and Apheris welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium.
AbbVie price target raised to $289 from $282 at BofA
BofA analyst Tim Anderson raised the firm’s price target on AbbVie (ABBV) to $289 from $282 and keeps a Buy rating on the shares. The company is well positioned for…
AbbVie announces FDA approval of Juvmo to treat Parkinson’s disease
AbbVie (ABBV) announced that the U.S. FDA has approved Juvmo tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with Parkinson’s disease, a progressive…
U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease
JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients a differentiated ap...
US FDA approves AbbVie's drug for Parkinson's disease
The US Food and Drug Administration has approved AbbVie's drug for Parkinson's disease in adults, the health regulator's website showed on Friday.
Allergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation Approach
AA Signature: SKIN360 marks the first in a series of assessment protocols addressing patients' evolving aesthetic goals. The program includes provider education and resources to support 96% of patient...
AbbVie: EC approves Rinvoq to treat polyarticular juvenile idiopathic arthritis
AbbVie (ABBV) announced that the European Commission has approved Rinvoq for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years of age and older who have respond...
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis
RINVOQ is now approved in the European Union for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients two years of age and older who have responded inadequately to, o...